Niagen+ Announces U.S. FDA Approval of ChromaDex’s First Pharmaceutical-Grade Injectable Niagen®
ChromaDex has announced the launch of Niagen+, the first pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Approved by the U.S. FDA for compounding by 503B outsourcing facilities, this intravenous (IV) and injectable NRC will be available in shot and push forms exclusively at clinics with a prescription.
ChromaDex aims offer Niagen as both a consumer dietary supplement, marketed globally as Tru Niagen®, and as a pharmaceutical-grade injectable product.
The intravenous form of Niagen is a new product which aims to tap into the growing intravenous hydration therapy market
Pharmaceutical-grade Niagen, including Niagen IV, plans for wider distribution nationwide.
Recent findings from a human clinical trial published on MedRxiv indicate that a 500 mg dose of Niagen IV was well-tolerated, with no adverse side effects. Compared to conventional NAD+ IV, Niagen IV demonstrated better tolerability, significantly reduced infusion time, and higher blood NAD+ levels shortly after infusion.
The traditional NAD+ IV treatment was associated with uncomfortable side effects, including headaches and nausea. In comparison to conventional NAD+ IV, Niagen IV exhibited superior tolerability, reduced infusion times, and higher blood NAD+ levels shortly after infusion.
